McKesson

MCK

Market cap $88.4B

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today the successful completion of the previously announced minority ownership interest investment from funds managed by affiliates of Apollo (“Apollo Funds”) in McKesson's Medical-Surgical Solutions (“MMS”) business on June 1, 2026. This transaction represents a key milestone in McKesson's intention to separate MMS into an independent, publicly traded company, and positions the business for long-term growth. Apollo Fund.

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.

McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

McKesson NYSE: MCK reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and prescription technology businesses, while outlining plans for continued earnings growth in fiscal 2027.

McKesson beats Q4 EPS estimates as oncology and specialty distribution growth offset revenue miss and lift segment margins.

McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript

Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.